Kymera Therapeutics Inc. (KYMR)
30.14
-1.21 (-3.86%)
At close: Mar 03, 2025, 3:59 PM
Kymera Therapeutics Cash Flow Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
| Net Income | -223.86M | -146.96M | -154.81M | -100.22M | -45.59M | -41.25M | -21.47M |
| Depreciation & Amortization | 7.37M | 3.56M | 2.98M | 2.4M | 1.76M | 825K | 205K |
| Stock-Based Compensation | 55.01M | 43.12M | 35.48M | 24.97M | 5.19M | 1.2M | 648K |
| Other Working Capital | -38.66M | -7.73M | -37.88M | -71.26M | 117.58M | 55.78M | 1.48M |
| Other Non-Cash Items | -9.06M | -5.23M | 889K | 5.83M | 332K | 443K | 443K |
| Deferred Income Tax | n/a | n/a | n/a | n/a | 1.57M | n/a | n/a |
| Change in Working Capital | -23.97M | 2.68M | -37.62M | -61.92M | 124.87M | 56.69M | 2.31M |
| Operating Cash Flow | -194.5M | -102.83M | -153.09M | -128.95M | 88.13M | 17.91M | -17.86M |
| Capital Expenditures | -12.84M | -34.48M | -2.84M | -1.6M | -9.1M | -532K | -1.36M |
| Acquisitions | n/a | n/a | -20.52M | 5.81M | 413.49M | n/a | n/a |
| Purchase of Investments | -901.23M | -189.15M | -445.97M | -456.4M | -529.38M | -15.95M | n/a |
| Sales Maturities Of Investments | 496M | 363.52M | 469.33M | 358.17M | 115.89M | n/a | n/a |
| Other Investing Acitivies | 13.98M | n/a | 20.52M | -5.81M | -413.49M | -15.95M | n/a |
| Investing Cash Flow | -404.08M | 139.89M | 20.52M | -99.83M | -422.59M | -16.49M | -1.36M |
| Debt Repayment | -1.58M | -76K | -1.13M | -849K | -554K | -371K | -295K |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 13.81M | 4.27M | 4.3M | 8.02M | 93.14M | 35.28M | 53.23M |
| Financial Cash Flow | 608.85M | 4.19M | 153M | 250.28M | 289.26M | 34.91M | 52.93M |
| Net Cash Flow | 10.27M | 41.25M | 20.43M | 21.5M | -45.2M | 36.33M | 33.71M |
| Free Cash Flow | -207.34M | -137.31M | -155.92M | -130.54M | 79.03M | 17.37M | -19.22M |